A potential 4th COVID-19 vaccine: Why it matters as vaccination rates climb
A fourth U.S.-based COVID-19 vaccine has proven effective in preventing serious illness from coronavirus, according to Phase 3 data from the company, Novavax. The two-dose Novavax shot had a 90.4% efficacy in trials using nearly 30,000 participants, including 100% efficacy against moderate and severe COVID-19 illness. Whether the shot will have the same path to getting emergency use authorization in the U.S. as the three prior vaccine company remains to be seen. Unlike the mRNA vaccines, the Novavax shot wouldn’t require the same cold storage that has caused struggles for some providers. As of Monday, June 21, nearly 4.8 million Michigan residents had gotten a first dose of COVID-19 vaccine, or 55.8% of residents 12 and older.mlive.com
Novavax: Large study finds COVID-19 shot about 90% effective
Vaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico. The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said. While demand for COVID-19 shots in the U.S. has dropped off dramatically, the need for more vaccines around the world remains critical.news.yahoo.com
Meet the women at forefront of COVID-19 vaccine development
She's one of the lead vaccine scientists at Novavax, a Maryland biotech company in the final trials of its COVID-19 vaccine. Her team isn't just led by a woman, it's almost all women. "I was told I was one of the first people to open a vial of the vaccine," Corbett said. Evan Vucci / APPatel has a theory as to why women are at the forefront: "We have a power inside us. Before the pandemic, the number of women in science and engineering was rising, up 36% over the past decade.cbsnews.com
Stocks making the biggest moves midday: Ulta, Alibaba, Netflix & more
Ulta Beauty — Shares of the cosmetics company fell more than 6% after reporting full-year same-store sales and revenue guidance below Wall Street estimates. Netflix — Shares of the streaming service slipped 1.8% after Netflix announced it would be testing a crackdown on password sharing. According to people with knowledge of the matter, the fine could exceed the $975 million fine that Qualcomm paid in 2015. JMP Securities praised the quarter in a note to clients but did point out that billings growth decelerated quarter over quarter. The company however, reported revenue that topped analyst estimates.cnbc.com
Stocks making the biggest moves premarket: Ulta, Poshmark, Novavax and others
Check out the companies making headlines before the bell:Ulta Beauty (ULTA) – Ulta Beauty announced that CEO Mary Dillon will step down in June to be replaced by company President David Kimbell. Separately, the cosmetics retailer beat estimates on the top and bottom lines for its latest quarter, but did cut its fiscal 2021 comparable sales outlook. Ulta lost 8.2% in premarket trading. Poshmark (POSH) – Poshmark reported better-than-expected sales for its latest quarter, but the online retailer of secondhand goods issued a current-quarter forecast that was short of analyst estimates. Vail did say visitation trends improved throughout the quarter, and shares surged 9.7% premarket.cnbc.com
Stocks making the biggest moves midday: Rocket Mortgage, Novavax, TripAdvisor and more
Novavax — Shares of Novavax slipped more than 15% after missing on the top and bottom lines of its quarterly results. Novavax reported a loss of $2.70 per share, compared to the loss of $1.49 per share expected on Wall Street, according to Refinitiv. The company said sales reached $127.7 million during the period, short of the expected $131.3 million, according to analysts surveyed by Refinitiv. Analysts expected earnings per share of $2.54 on revenue of $27.48 billion. Analysts polled by Refinitiv expected earnings per share of $1.01 on revenue of $5.86 billion.cnbc.com
Stocks making the biggest moves in the premarket: Zoom Video, Novavax, Nio & more
Take a look at some of the biggest movers in the premarket:Zoom Video (ZM) – Zoom reported quarterly profit of $1.22 per share, beating the consensus estimate of 79 cents a share. Target (TGT) – The retailer reported quarterly earnings of $2.67 per share, 13 cents a share above estimates. Kohl's (KSS) – Kohl's reported quarterly profit of $2.22 per share, including $1.15 a share in incremental tax benefits. Nio (NIO) – Nio fell 5.2% in premarket trading after it reported a larger-than-expected loss for its latest quarter. AutoZone (AZO) – The auto parts retailer reported quarterly profit of $14.93 per share, beating the consensus estimate of $12.84 a share.cnbc.com
Drugmaker Novavax begins late-stage vaccine trial in UK
LONDON – U.S.-based Novavax has begun a late stage trial of its potential COVID-19 vaccine in the United Kingdom because the high-level of the coronavirus circulating in the country is likely to produce quick results, the pharmaceutical company said. Novavax plans to test the effectiveness of its vaccine in a trial involving 10,000 people between the ages of 18 and 84, according to a statement issued late Thursday. The trial is being conducted in partnership with the U.K. government’s Vaccine Taskforce, which was created in April to help speed the development of a COVID-19 vaccine. The U.K. has already agreed to buy 60 million doses of the Novavax vaccine to ensure it can be distributed as quickly as possible if it is approved by regulators. The government said Friday that participants in the Novavax trial will be drawn from the 250,000 people who have volunteered to take part in COVID-19 vaccine testing through the National Health Service’s Vaccine Registry.
Stocks post solid gains as technology shares lead rally
Despite the rally, the S&P 500 still posted its fourth straight weekly loss, extending Wall Street's September swoon. The S&P 500 rose 1.6% after flip-flopping between small gains and losses a few times in the early going. The S&P 500 came within striking distance of a 10% drop from its all-time high earlier this week, what Wall Street calls a correction. The S&P 500 rose 51.87 points to 3,298.46. Norwegian Cruise Line notched the biggest gain in the S&P 500, vaulting 13.7%.
The Latest: Concerns over coronavirus upticks in California
The directive comes amid concerns about an uptick in coronavirus cases in certain Brooklyn and Queens neighborhoods with large Orthodox Jewish populations. New York City’s current overall infection rate remains low, but official figures indicate the affected neighborhoods accounted for 20% of the city’s coronavirus cases in recent weeks. ___BOSTON — An outbreak of coronavirus infections at a major Boston hospital has grown to 19 confirmed cases. ___DES MOINES, Iowa — Iowa has reported a jump of 1,086 new coronavirus cases, the second consecutive day of new cases exceeding 1,000. There are currently nearly 985,000 worldwide coronavirus deaths.
Trump to visit North Carolina, cite work on COVID-19 vaccine
WASHINGTON The White House says President Donald Trump will visit North Carolina on Monday to tour a business that is participating in work on a COVID-19 vaccine. The White House said Trump is expected to speak about the collaboration between the administration and the private sector to rapidly develop a vaccine and ensure rapid distribution once ready. North Carolina is a key battleground state in the coming election, and Trumps visit marks his 10th trip to the state during his presidency. The biotechnology facility Trump will visit is the FUJIFILM Diosynth Biotechnologies Innovation Center in Morrisville, a suburb of Raleigh. The White House said the company is manufacturing key components of a COVID-19 vaccine candidate being developed by Novavax, an American vaccine development company based in Maryland.
US company trials coronavirus vaccine candidate in Australia
In this photo released by Nucleus Network/ABC, clinical trial participants are given a coronavirus vaccine in Melbourne, Australia, Tuesday, May 26, 2020, with hopes of releasing a proven vaccine this year. Novavax will inject 131 volunteers in the first phase of the trial testing the safety of the vaccine and looking for signs of its effectiveness. (Patrick Rocca/Nucleus Network/ABC via AP)CANBERRA A U.S. biotechnology company began injecting a coronavirus vaccine candidate into people in Australia on Tuesday with hopes of releasing a proven vaccine this year. Novavax used genetic engineering to grow harmless copies of the coronavirus spike protein in giant vats of insect cells in a laboratory. The way we make a vaccine is we never touch the virus, Novavax told The Associated Press last month.